D.A. Davidson & Co. Spero Therapeutics, Inc. Transaction History

D.A. Davidson & Co.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 28, 2022	SELL	$0.74 - $7.44 $24,420 - $245,520	-33,000 Reduced 75.34%	10,800 $8,000
Q4 2021 Jan 31, 2022	BUY	$13.09 - $18.77 $10,472 - $15,016	800 Added 1.86%	43,800 $701,000
Q3 2021 Nov 15, 2021	BUY	$13.03 - $19.51 $117,270 - $175,590	9,000 Added 26.47%	43,000 $792,000
Q2 2021 Aug 10, 2021	BUY	$12.22 - $15.79 $6,110 - $7,895	500 Added 1.49%	34,000 $475,000
Q1 2021 May 07, 2021	BUY	$13.23 - $21.48 $46,305 - $75,180	3,500 Added 11.67%	33,500 $493,000
Q4 2020 Feb 10, 2021	BUY	$11.65 - $22.07 $5,825 - $11,035	500 Added 1.69%	30,000 $582,000
Q3 2020 Nov 02, 2020	BUY	$8.96 - $14.12 $68,992 - $108,724	7,700 Added 35.32%	29,500 $329,000
Q2 2020 Aug 10, 2020	BUY	$7.27 - $14.18 $49,436 - $96,424	6,800 Added 45.33%	21,800 $295,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $28,380 - $36,480	3,000 Added 25.0%	15,000 $144,000
Q3 2019 Nov 05, 2019	BUY	$9.01 - $12.55 $18,020 - $25,100	2,000 Added 20.0%	12,000 $127,000
Q2 2019 Aug 13, 2019	BUY	$10.25 - $14.36 $102,500 - $143,600	10,000 New	10,000 $115,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.